- Email: [email protected]
Alfred Marchionini Prize—1997
Journal of the American Academy of Dermatology Volume 34, Number 4
sis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969;29:705-27. 4. Kopf AW, Welkovich B, Frankel RE, et al. Thickness of malignant melanoma: global analysis of related factors. J Dermatol Surg Oncol 1987;13:345-90, 401-20. 5. Balch CM, Mumd TM, Soong SJ, et al. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 1978;188:732-42. 6. Van Der Esch EP, Cascinelli N, Preda F, et al. Stage 1 melanoma of the skin: evaluation of prognosis according to histologic characteristics. Cancer 1981;48:1668-73. 7. Day CL, Mihm MC, Sober AJ, et al. Prognostic factors for melanoma patients with lesions 0.76-1.69 mm in thickness: an appraisal of "thin" level IV lesions. Ann Surg 1982; 195:30-4. 8. Kelly JW, Sagebiei RW, Clyman S, et al. Thin level IV malignant melanoma. A subset in which level is the major prognostic indicator. Ann Surg 1985;202:98-103. 9. Pritchard GA, Hughes LE. Clinical assessment of melanoma thickness. Eur J SurgOncol 1989;15:232-5. 1'0. Taylor BA, Hughes LE. A policy of selective excision for
O'DonneU et al.
11. 12. 13. 14.
15.
16.
637
primary cutaneous malignant melanoma. Eur J Surg Oncol 1985;11:7-13. Neades GT, Orr DJA, Hughes LE, et al. Safe margins in the excision of primary cutaneous melanoma. Br J Surg 1993;80:731-3. Funk W, Schrnoeckel C, Holzel D, et al. Prognostic classification of malignant melanoma by clinical criteria. Br J Dermatol 1984;111:129-38. National Institutes of Health Consensus Conference. Diagnosis and treatment of early melanoma. JAMA 1992;268: 1314-9. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage 1 primary cutaneous malignant melanoma: comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988; 318:1159-62. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-era surgical margins for intermediate-thickness melanomas (1 to 4 mm): results of a multi-institutional randomized surgical trial. Ann Surg 1993;218:262-9. Ho VC, Sober AJ. Therapy for cutaneous melanoma: an update. J AM AC.ADDERMATOL1990;22:159-76.
ALFRED M A R C H I O N I N I P R I Z E - - 1 9 9 7 The XIX Congressus Mundi Dermatologiae, which is to be held in 1997 in Sydney, Australia, has been chosen as the venue for the Alfred Marchionini Prize award ceremony. The prize consists of two parts: Alfred Marchionini Gold Medal and the Alfred Marchionini Research Prize. Eligible for the Alfred Marchionini Research Prize are deserving young scientists (university lecturers, senior physicians, and scientific assistants from the medical faculty [including veterinary and dental science] as well as from the fields of biochemistry and biopharmacy). Candidates of all nationalities will be eligible. The prize will be awarded for personal characteristics as well as dedication to international communication as promoted by Alfred Marchionini and the candidate's scientific contribution to date, which must be of particular importance for international dermatology. Nominations for the Alfred Marchionini Research Prize may be made by the Alfred Marchionini Foundation, members of the Board of Trustees, and the heads of clinics, research establishments, and other scientific institutes and societies. Nominations should include a comprehensive evaluation of the candidate, giving valid reasons for his or her suitability as an award winner and all documentation necessary for proper consideration of the candidate by the Board of Trustees. Nominations should be submitted to the Chairman of the Board of Trustees of the Alfred Marchionini Prize Foundation no later than J u n e 30, 1996, to the following address: Professor H. H. Wolff, MD Director of the University Dermatological Clinic Ltibeck Ratzeburger Allee 160 D-23538 Ltibeck, Germany or
Director of the Alfred Marchionini Foundation for the Furtherance of Medical Science Danzigerstrasse 5 D-21465 Reibek, Germany
sis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969;29:705-27. 4. Kopf AW, Welkovich B, Frankel RE, et al. Thickness of malignant melanoma: global analysis of related factors. J Dermatol Surg Oncol 1987;13:345-90, 401-20. 5. Balch CM, Mumd TM, Soong SJ, et al. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 1978;188:732-42. 6. Van Der Esch EP, Cascinelli N, Preda F, et al. Stage 1 melanoma of the skin: evaluation of prognosis according to histologic characteristics. Cancer 1981;48:1668-73. 7. Day CL, Mihm MC, Sober AJ, et al. Prognostic factors for melanoma patients with lesions 0.76-1.69 mm in thickness: an appraisal of "thin" level IV lesions. Ann Surg 1982; 195:30-4. 8. Kelly JW, Sagebiei RW, Clyman S, et al. Thin level IV malignant melanoma. A subset in which level is the major prognostic indicator. Ann Surg 1985;202:98-103. 9. Pritchard GA, Hughes LE. Clinical assessment of melanoma thickness. Eur J SurgOncol 1989;15:232-5. 1'0. Taylor BA, Hughes LE. A policy of selective excision for
O'DonneU et al.
11. 12. 13. 14.
15.
16.
637
primary cutaneous malignant melanoma. Eur J Surg Oncol 1985;11:7-13. Neades GT, Orr DJA, Hughes LE, et al. Safe margins in the excision of primary cutaneous melanoma. Br J Surg 1993;80:731-3. Funk W, Schrnoeckel C, Holzel D, et al. Prognostic classification of malignant melanoma by clinical criteria. Br J Dermatol 1984;111:129-38. National Institutes of Health Consensus Conference. Diagnosis and treatment of early melanoma. JAMA 1992;268: 1314-9. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage 1 primary cutaneous malignant melanoma: comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988; 318:1159-62. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-era surgical margins for intermediate-thickness melanomas (1 to 4 mm): results of a multi-institutional randomized surgical trial. Ann Surg 1993;218:262-9. Ho VC, Sober AJ. Therapy for cutaneous melanoma: an update. J AM AC.ADDERMATOL1990;22:159-76.
ALFRED M A R C H I O N I N I P R I Z E - - 1 9 9 7 The XIX Congressus Mundi Dermatologiae, which is to be held in 1997 in Sydney, Australia, has been chosen as the venue for the Alfred Marchionini Prize award ceremony. The prize consists of two parts: Alfred Marchionini Gold Medal and the Alfred Marchionini Research Prize. Eligible for the Alfred Marchionini Research Prize are deserving young scientists (university lecturers, senior physicians, and scientific assistants from the medical faculty [including veterinary and dental science] as well as from the fields of biochemistry and biopharmacy). Candidates of all nationalities will be eligible. The prize will be awarded for personal characteristics as well as dedication to international communication as promoted by Alfred Marchionini and the candidate's scientific contribution to date, which must be of particular importance for international dermatology. Nominations for the Alfred Marchionini Research Prize may be made by the Alfred Marchionini Foundation, members of the Board of Trustees, and the heads of clinics, research establishments, and other scientific institutes and societies. Nominations should include a comprehensive evaluation of the candidate, giving valid reasons for his or her suitability as an award winner and all documentation necessary for proper consideration of the candidate by the Board of Trustees. Nominations should be submitted to the Chairman of the Board of Trustees of the Alfred Marchionini Prize Foundation no later than J u n e 30, 1996, to the following address: Professor H. H. Wolff, MD Director of the University Dermatological Clinic Ltibeck Ratzeburger Allee 160 D-23538 Ltibeck, Germany or
Director of the Alfred Marchionini Foundation for the Furtherance of Medical Science Danzigerstrasse 5 D-21465 Reibek, Germany